Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM9GZW6)

Drug Name
Vabicaserin Drug Info
Synonyms Vabicaserin hydrochloride; PF-05208769; PF-5208769; SCA-136; WY-16629
Indication
Disease Entry ICD 11 Status REF
Psychotic disorder 6A20-6A25 Phase 2 [1]
Cross-matching ID
PubChem CID
11521822
CAS Number
CAS 887258-95-9
TTD Drug ID
DM9GZW6

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 2B receptor (HTR2B) TT0K1SC 5HT2B_HUMAN Modulator [2] , [3]
5-HT 2C receptor (HTR2C) TTWJBZ5 5HT2C_HUMAN Modulator [2] , [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
5-HT 2C receptor (HTR2C) DTT HTR2C 4.233 3.329 3.843 3.888
5-HT 2B receptor (HTR2B) DTT HTR2B 0.485 3.536 0.379 4.667
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Psychotic disorder
ICD Disease Classification 6A20-6A25
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
5-HT 2C receptor (HTR2C) DTT HTR2C 8.66E-01 -0.13 -0.12
5-HT 2B receptor (HTR2B) DTT HTR2B 2.08E-01 -0.05 -0.23
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00768612) Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia. U.S. National Institutes of Health.
2 Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
3 Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist. J Pharmacol Exp Ther. 2011 Jun;337(3):673-80.